Menu UF Health Home Menu
 

John R. Wingard, MD

John R. Wingard, MD
Price Eminent Scholar and Professor of Medicine
Deputy Director for Research, UF Health Cancer Center
Director, Bone Marrow Transplant Program

PO Box 103633
Gainesville, FL 32610-3633

TEL: (352) 273-8022
FAX: (352) 273-8109

Dr. Wingard is a physician scientist and is board certified in oncology, hematology and internal medicine. He holds leaderships positions within the Division of Hematology & Oncology, as well as within the College of Medicine and the University of Florida Shands Cancer Center.

Degree/Program

Institution

Field/Specialty

MD The Johns Hopkins University  
Residency  University of Tennessee College of Medicine Internal Medicine
Fellowship Johns Hopkins Hospitals Oncology

Academic/Research Interests:

Dr. Wingard’s broad research effort is in exploring various strategies to optimize hematopoietic stem cell transplantation outcomes, provide state-of-the-art care for leukemia and other hematological malignancies, and to explore new applications of stem cell transplantation. His areas of funded research include conduction of phase III clinical trials of transplant strategies, conduction of clinical trials of cellular therapies of cardiovascular diseases and development of new diagnostics.

Clinical Interests:

Dr. Wingard is the Program Director for the Bone Marrow Transplant Unit. His clinical interests include the treatment of hematological malignancies through bone marrow and stem cell transplantation.

Publications:

  • Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011 Feb;25(1):101-16.
  • Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Bolwell B, Armenian S, Baker KS, Di Bartolomeo P, Bhatia S, Burns LJ, Cahn JY, Chen J, Eapen M, Gajewski JL, Gupta V, Hale GA, Halter J, Horowitz MM, Jakubowski AA, Kolb HJ, Hayes-Lattin BM, Lazarus HM, Loren AW, Marks DI, Reddy V, Schouten HC, Tichelli A, Warwick AB, Wood WA, Bolwell B, Rizzo JD, Socié G,  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.  J Clin Oncol, 2011:  29 (16):  2230-2239.
  • Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O’Donnell PV.  Alternative donor transplantation:  results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts.  Blood, 2011; 118(2):  282-288.
  • Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather H, Confer DL, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPersio JF, Boeckh M, and Marr KA. Randomized Double-blind Trial of Fluconazole vs Voriconazole for Prevention of Invasive Fungal Infection after Allogeneic Hematopoietic Cell Transplantation.  Blood, 2010; Dec 9;116(24):5111-8.
  • Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather H, Confer DL, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPersio JF, Boeckh M, and Marr KA. Randomized Double-blind Trial of Fluconazole vs Voriconazole for Prevention of Invasive Fungal Infection after Allogeneic Hematopoietic Cell Transplantation.  Blood, 2010; Dec 9;116(24):5111-8.

Please click here for a list of Dr. Wingard’s industry relationships.